Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Gain Therapeutics (GANX) over the last 3 years, with Q3 2025 value amounting to $400000.0.

  • Gain Therapeutics' Receivables - Net changed N/A to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year change of. This contributed to the annual value of $81862.0 for FY2021, which is 85767.43% up from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Receivables - Net is $400000.0.
  • Gain Therapeutics' 5-year Receivables - Net high stood at $400000.0 for Q2 2025, and its period low was $4486.0 during Q1 2021.